News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Immunicum's Patent Application Regarding the Company’s Core-Technology for Therapeutic Cancer Vaccination Using Allogeneic Dendritic Cells is Being Approved in the U.S.


10/25/2013 9:34:54 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Gothenburg, Sweden, 2013-10-25 08:53 CEST (GLOBE NEWSWIRE) -- The United States Patent and Trademark Office (USPTO), has issued a notice of allowance regarding patent application 11/603,819 and thus intends to approve Immunicum’s patent application to protect the Company’s core-technology in the U.S. market.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
Immunicum
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES